NCT05447208

Effect of GH on the Blastocyst Euploid Rate in AMA Patients

A Randomized Control Trial to Investigate the Effect of Growth Hormone on the Euploid Rate of Blastocyst in Patients With Advanced Maternal Age

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: ShangHai Ji Ai Genetics & IVF Institute · Academic / Other
• Sex: Female
• Age: 38 Years
• Healthy volunteers: Not accepted

Summary

This randomized trial aims to compare the euploid rate of blastocysts in AMA patients undergoing PGT-A (preimplantation genetic testing for aneuploidy) with or without growth hormone supplement. Infertile patients ≥38 years old will be recruited for study after informed consent if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Treatment group: Women will receive growth hormone (GH) supplement before and during antagonist protocol for ovarian stimulation. Control group: Women will receive antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts.

Conditions

• Preimplantation Genetic Testing
• Growth Hormone
• Age, Parental

Interventions

Type	Name	Description
DRUG	Growth Hormone	Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
DRUG	GnRH antagonist	GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger

Timeline

• Start date: 2022-08-01
• Primary completion: 2026-03-01
• Completion: 2026-12-31
• First posted: 2022-07-07
• Last updated: 2025-02-12

Locations

1 site across 1 country: China